Yubo International Biotech Ltd financial data

Symbol
YBGJ on OTC
Location
Beijing, China
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 16% % -18%
Quick Ratio 0.88% % -74%
Debt-to-equity -135% % 19%
Return On Equity 46% % -47%
Return On Assets -122% % 1.7%
Operating Margin 7691278% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 170,416,343 shares 42%
Entity Public Float $43,391 USD
Weighted Average Number of Shares Outstanding, Diluted 147,870,790 shares 23%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $18 USD -100%
Operating Income (Loss) $1,384,430 USD 28%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,380,078 USD 36%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $1,432,048 USD 30%
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,926 USD 36%
Inventory, Net $37,889 USD 476%
Assets, Current $649,563 USD -10%
Property, Plant and Equipment, Net $84,645 USD -67%
Operating Lease, Right-of-Use Asset $138,604 USD -76%
Intangible Assets, Net (Excluding Goodwill) $43,241 USD -23%
Assets $953,211 USD -42%
Liabilities, Current $2,555,316 USD -43%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $2,555,316 USD -46%
Accumulated Other Comprehensive Income (Loss), Net of Tax $176,450 USD 34%
Retained Earnings (Accumulated Deficit) $7,478,641 USD -17%
Stockholders' Equity Attributable to Parent $1,662,888 USD 47%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1,602,105 USD 47%
Liabilities and Equity $953,211 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $392,045 USD -19%
Net Cash Provided by (Used in) Financing Activities $277,780 USD -9.9%
Net Cash Provided by (Used in) Investing Activities $6,186 USD 79%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,758 USD -95%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,926 USD 36%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $2,128,984 USD 47%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.17 pure 0%
Operating Lease, Liability $138,604 USD -76%
Payments to Acquire Property, Plant, and Equipment $6,186 USD -67%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $1,332,774 USD 41%
Lessee, Operating Lease, Liability, to be Paid $157,712 USD -74%
Property, Plant and Equipment, Gross $152,809 USD -45%
Operating Lease, Liability, Current $138,604 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Two $110,112 USD 92%
Lessee, Operating Lease, Liability, to be Paid, Year One $79,742 USD -80%
Lessee, Operating Lease, Liability, to be Paid, Year Three $79,742 USD
Deferred Tax Assets, Operating Loss Carryforwards $1,448,377 USD
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) $467,297 USD -356%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $5,514,423 USD 84%
Amortization of Intangible Assets $11,652 USD -12%
Depreciation, Depletion and Amortization $164,068 USD -32%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $18,000 USD 36635%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%